IL101738A - תכשירי רוקחות לשיפור תסמינים של דמנציה בבני אדם המכילים -n -)-2,6דימתילפניל(--2)-2אוקסו--1 פירולידיניל( אצטאמיד או מלח שלה - Google Patents
תכשירי רוקחות לשיפור תסמינים של דמנציה בבני אדם המכילים -n -)-2,6דימתילפניל(--2)-2אוקסו--1 פירולידיניל( אצטאמיד או מלח שלהInfo
- Publication number
- IL101738A IL101738A IL10173892A IL10173892A IL101738A IL 101738 A IL101738 A IL 101738A IL 10173892 A IL10173892 A IL 10173892A IL 10173892 A IL10173892 A IL 10173892A IL 101738 A IL101738 A IL 101738A
- Authority
- IL
- Israel
- Prior art keywords
- dementia
- pharmaceutical composition
- symptoms
- mental
- dimethylphenyl
- Prior art date
Links
- 208000024891 symptom Diseases 0.000 title claims abstract description 30
- 206010012289 Dementia Diseases 0.000 title claims abstract description 22
- 230000003340 mental effect Effects 0.000 title claims abstract description 21
- 150000003839 salts Chemical class 0.000 title claims abstract description 6
- NGHTXZCKLWZPGK-UHFFFAOYSA-N nefiracetam Chemical compound CC1=CC=CC(C)=C1NC(=O)CN1C(=O)CCC1 NGHTXZCKLWZPGK-UHFFFAOYSA-N 0.000 title claims abstract description 5
- 239000008194 pharmaceutical composition Substances 0.000 title claims description 13
- 208000024827 Alzheimer disease Diseases 0.000 claims abstract description 15
- 230000007423 decrease Effects 0.000 claims abstract description 10
- 230000006870 function Effects 0.000 claims abstract description 10
- 208000013677 cerebrovascular dementia Diseases 0.000 claims abstract description 8
- 206010000117 Abnormal behaviour Diseases 0.000 claims abstract description 7
- 230000004970 emotional disturbance Effects 0.000 claims abstract description 7
- 239000004480 active ingredient Substances 0.000 claims abstract description 4
- 239000002775 capsule Substances 0.000 claims description 2
- 239000006187 pill Substances 0.000 claims description 2
- 239000000725 suspension Substances 0.000 claims description 2
- -1 erriulsion Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 20
- 239000003814 drug Substances 0.000 abstract description 11
- 229940079593 drug Drugs 0.000 abstract description 8
- 230000008450 motivation Effects 0.000 abstract description 8
- 230000003247 decreasing effect Effects 0.000 abstract description 6
- 239000003795 chemical substances by application Substances 0.000 abstract description 2
- 229940126062 Compound A Drugs 0.000 description 23
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 23
- 230000006872 improvement Effects 0.000 description 17
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 9
- 201000010099 disease Diseases 0.000 description 7
- 238000002591 computed tomography Methods 0.000 description 6
- 238000010171 animal model Methods 0.000 description 4
- 230000002996 emotional effect Effects 0.000 description 4
- 230000006399 behavior Effects 0.000 description 3
- 208000026106 cerebrovascular disease Diseases 0.000 description 3
- 230000007012 clinical effect Effects 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 239000002664 nootropic agent Substances 0.000 description 3
- 238000011282 treatment Methods 0.000 description 3
- 230000002861 ventricular Effects 0.000 description 3
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 2
- 206010021639 Incontinence Diseases 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000004891 communication Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 230000008451 emotion Effects 0.000 description 2
- 230000036651 mood Effects 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 108010058699 Choline O-acetyltransferase Proteins 0.000 description 1
- 102100023460 Choline O-acetyltransferase Human genes 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- MADRVGBADLFHMO-UHFFFAOYSA-N Indeloxazine Chemical compound C=1C=CC=2C=CCC=2C=1OCC1CNCCO1 MADRVGBADLFHMO-UHFFFAOYSA-N 0.000 description 1
- 206010061216 Infarction Diseases 0.000 description 1
- 208000015710 Iron-Deficiency Anemia Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 206010039966 Senile dementia Diseases 0.000 description 1
- 201000004810 Vascular dementia Diseases 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 208000024823 antisocial personality disease Diseases 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 230000003920 cognitive function Effects 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 229940099112 cornstarch Drugs 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 230000002008 hemorrhagic effect Effects 0.000 description 1
- KEBHLNDPKPIPLI-UHFFFAOYSA-N hydron;2-(3h-inden-4-yloxymethyl)morpholine;chloride Chemical compound Cl.C=1C=CC=2C=CCC=2C=1OCC1CNCCO1 KEBHLNDPKPIPLI-UHFFFAOYSA-N 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 229960004333 indeloxazine Drugs 0.000 description 1
- 230000007574 infarction Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000001777 nootropic effect Effects 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Psychiatry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hospice & Palliative Care (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pyrrole Compounds (AREA)
- Steroid Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Materials For Medical Uses (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
- Medicinal Preparation (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP22981891 | 1991-05-02 | ||
| JP22981991 | 1991-05-02 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IL101738A0 IL101738A0 (en) | 1992-12-30 |
| IL101738A true IL101738A (he) | 1999-01-26 |
Family
ID=26529012
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL10173892A IL101738A (he) | 1991-05-02 | 1992-04-30 | תכשירי רוקחות לשיפור תסמינים של דמנציה בבני אדם המכילים -n -)-2,6דימתילפניל(--2)-2אוקסו--1 פירולידיניל( אצטאמיד או מלח שלה |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US5886023A (he) |
| EP (1) | EP0515866B1 (he) |
| KR (1) | KR100310590B1 (he) |
| AT (1) | ATE203402T1 (he) |
| AU (2) | AU1595492A (he) |
| CA (1) | CA2067614C (he) |
| CZ (1) | CZ281170B6 (he) |
| DE (1) | DE69231955T2 (he) |
| DK (1) | DK0515866T3 (he) |
| ES (1) | ES2160097T3 (he) |
| GR (1) | GR3036970T3 (he) |
| HU (1) | HU224689B1 (he) |
| IE (1) | IE921377A1 (he) |
| IL (1) | IL101738A (he) |
| MX (1) | MX9202058A (he) |
| NO (1) | NO312813B1 (he) |
| PT (1) | PT515866E (he) |
| RU (1) | RU2070042C1 (he) |
| SG (1) | SG49650A1 (he) |
| SK (1) | SK279285B6 (he) |
| TW (1) | TW199096B (he) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU727482B2 (en) * | 1996-10-01 | 2000-12-14 | Daiichi Pharmaceutical Co., Ltd. | Mitochondrial membrane stabilizer |
| EP1020189B1 (en) | 1997-07-15 | 2004-05-12 | Daiichi Pharmaceutical Co., Ltd. | Nefiracetam for prevention and treatment of amnesia caused by propofol |
| IT1312107B1 (it) * | 1999-05-14 | 2002-04-04 | Umberto Cornelli | Glicosaminoglicani aventi peso molecolare medio di 2400 d atti altrattamento della demenza senile |
| EP1180366A1 (en) * | 1999-05-31 | 2002-02-20 | Daiichi Pharmaceutical Co., Ltd. | Neuronal death inhibitors |
| US20040077709A1 (en) * | 1999-05-31 | 2004-04-22 | Daiichi Pharmaceutical Co., Ltd. | Neuronal death inhibitors |
| US6376489B1 (en) * | 1999-12-23 | 2002-04-23 | Icos Corporation | Cyclic AMP-specific phosphodiesterase inhibitors |
| US6423739B1 (en) | 2000-02-23 | 2002-07-23 | Daiichi Pharmaceutical Co., Ltd. | Method for aiding cerebral recovery following neurodegeneration |
| GB0004297D0 (en) * | 2000-02-23 | 2000-04-12 | Ucb Sa | 2-oxo-1 pyrrolidine derivatives process for preparing them and their uses |
| US6348489B1 (en) | 2000-04-11 | 2002-02-19 | Daiichi Pharmaceutical Co., Ltd. | Method of treating traumatic brain injury and other neuronal disorders |
| KR100823668B1 (ko) * | 2000-12-28 | 2008-04-21 | 해밀턴 파마슈티컬스 인코포레이티드 | 신경성 통증 치료 및 예방약 |
| CA2457982C (en) * | 2001-08-22 | 2009-11-03 | Daiichi Pharmaceutical Co., Ltd. | Use of nefiracetam for treating neurodegeneration |
| US20060241144A1 (en) * | 2005-04-20 | 2006-10-26 | Albert Cha | Method for treating apathy syndrome |
| US7972633B2 (en) * | 2007-02-07 | 2011-07-05 | Applied Cognitive Sciences, LLC | Nutritional supplements for healthy memory and mental function |
| RU2327480C1 (ru) * | 2007-05-23 | 2008-06-27 | Виктор Иванович Рощин | Активный ингредиент лекарственного средства, лекарственное средство, фармацевтическая композиция и способ лечения больных с дементным синдромом |
| DK3260118T3 (da) * | 2008-10-16 | 2021-04-19 | Univ Johns Hopkins | Fremgangsmåder og sammensætninger til forbedring af kognitiv funktion |
| EA202092673A3 (ru) * | 2010-02-09 | 2021-05-31 | Дзе Джонс Хопкинс Юниверсити | Способы и композиции для улучшения когнитивной функции |
| US20140206667A1 (en) | 2012-11-14 | 2014-07-24 | Michela Gallagher | Methods and compositions for treating schizophrenia |
| WO2014144663A1 (en) | 2013-03-15 | 2014-09-18 | The Johns Hopkins University | Methods and compositions for improving cognitive function |
| AU2014228512A1 (en) | 2013-03-15 | 2015-10-01 | Agenebio, Inc. | Methods and compositions for improving cognitive function |
| CA2986598C (en) | 2015-05-22 | 2023-09-26 | Agenebio, Inc. | Extended release pharmaceutical compositions of levetiracetam |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BE864269A (fr) * | 1977-03-03 | 1978-06-16 | Parke Davis & Co | Nouveaux n-(aminoalkyl substitue)-2-oxo-1-pyrrolidine-acetamides et procedes pour les produire |
| IT1141287B (it) * | 1979-06-13 | 1986-10-01 | Nattermann A & Cie | Ammidi di acidi pirrolidin-(2)-on-(1)-ilalchil-carbossilici,procedimento per la loro preparazione e prodotti medicinali che le contengono |
| US4385053A (en) * | 1981-03-11 | 1983-05-24 | Barry Reisberg | Treatment for human memory impairment associated with aging |
| JPH0699307B2 (ja) * | 1987-08-20 | 1994-12-07 | キッセイ薬品工業株式会社 | 抗痴呆剤 |
| IT1231477B (it) * | 1989-07-12 | 1991-12-07 | Sigma Tau Ind Farmaceuti | (pirrolidin-2-one-1-il) acetammidi quali attivatori dei processi di apprendimento e della memoria e composizioni farmaceutiche comprendenti tali composti |
-
1992
- 1992-04-29 CA CA002067614A patent/CA2067614C/en not_active Expired - Lifetime
- 1992-04-29 SK SK1306-92A patent/SK279285B6/sk unknown
- 1992-04-29 CZ CS921306A patent/CZ281170B6/cs not_active IP Right Cessation
- 1992-04-30 IL IL10173892A patent/IL101738A/he active IP Right Grant
- 1992-04-30 SG SG1996002798A patent/SG49650A1/en unknown
- 1992-04-30 EP EP92107421A patent/EP0515866B1/en not_active Expired - Lifetime
- 1992-04-30 ES ES92107421T patent/ES2160097T3/es not_active Expired - Lifetime
- 1992-04-30 HU HU9201477A patent/HU224689B1/hu not_active IP Right Cessation
- 1992-04-30 AT AT92107421T patent/ATE203402T1/de not_active IP Right Cessation
- 1992-04-30 MX MX9202058A patent/MX9202058A/es not_active IP Right Cessation
- 1992-04-30 RU SU5011760/14A patent/RU2070042C1/ru not_active IP Right Cessation
- 1992-04-30 NO NO19921724A patent/NO312813B1/no unknown
- 1992-04-30 PT PT92107421T patent/PT515866E/pt unknown
- 1992-04-30 DE DE69231955T patent/DE69231955T2/de not_active Expired - Lifetime
- 1992-04-30 DK DK92107421T patent/DK0515866T3/da active
- 1992-05-01 KR KR1019920007433A patent/KR100310590B1/ko not_active Expired - Fee Related
- 1992-05-01 AU AU15954/92A patent/AU1595492A/en not_active Abandoned
- 1992-05-01 TW TW081103420A patent/TW199096B/zh active
- 1992-07-01 IE IE137792A patent/IE921377A1/en not_active IP Right Cessation
-
1995
- 1995-05-22 US US08/447,054 patent/US5886023A/en not_active Expired - Fee Related
- 1995-11-08 AU AU37745/95A patent/AU697936B2/en not_active Ceased
-
2001
- 2001-10-22 GR GR20010401840T patent/GR3036970T3/el not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| NO921724L (no) | 1992-11-03 |
| EP0515866A1 (en) | 1992-12-02 |
| ATE203402T1 (de) | 2001-08-15 |
| KR100310590B1 (ko) | 2001-12-28 |
| PT515866E (pt) | 2001-11-30 |
| ES2160097T3 (es) | 2001-11-01 |
| CA2067614A1 (en) | 1992-11-03 |
| AU3774595A (en) | 1996-03-07 |
| HUT62790A (en) | 1993-06-28 |
| US5886023A (en) | 1999-03-23 |
| KR920021143A (ko) | 1992-12-18 |
| DE69231955D1 (de) | 2001-08-30 |
| AU697936B2 (en) | 1998-10-22 |
| HK1002153A1 (en) | 1998-07-31 |
| RU2070042C1 (ru) | 1996-12-10 |
| DK0515866T3 (da) | 2001-09-24 |
| IL101738A0 (en) | 1992-12-30 |
| CA2067614C (en) | 2002-07-30 |
| NO312813B1 (no) | 2002-07-08 |
| NO921724D0 (no) | 1992-04-30 |
| AU1595492A (en) | 1992-11-05 |
| HU224689B1 (hu) | 2005-12-28 |
| TW199096B (he) | 1993-02-01 |
| EP0515866B1 (en) | 2001-07-25 |
| DE69231955T2 (de) | 2002-04-04 |
| SK279285B6 (sk) | 1998-09-09 |
| GR3036970T3 (en) | 2002-01-31 |
| HU9201477D0 (en) | 1992-07-28 |
| MX9202058A (es) | 1993-03-01 |
| SG49650A1 (en) | 1998-06-15 |
| CS130692A3 (en) | 1992-11-18 |
| CZ281170B6 (cs) | 1996-07-17 |
| IE921377A1 (en) | 1992-11-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL101738A (he) | תכשירי רוקחות לשיפור תסמינים של דמנציה בבני אדם המכילים -n -)-2,6דימתילפניל(--2)-2אוקסו--1 פירולידיניל( אצטאמיד או מלח שלה | |
| IE83506B1 (en) | Use of N-(2,6-dimethylphenyl)-2-(2-oxo-1- pyrrolidinyl)acetamide for the treatment of dementia | |
| US4663318A (en) | Method of treating Alzheimer's disease | |
| CA2294589A1 (en) | Composition for controlling mood disorders in healthy individuals | |
| Chadwick et al. | Acute intoxication with sodium valproate | |
| EP0825857B1 (en) | Use of gabapentin and its derivatives in the treatment of mania and bipolar disorder | |
| KR20060130649A (ko) | 근위축성 측색경화증(ａｌｓ) 또는 ａｌｓ에 기인하는질환의 신규 치료제 | |
| JPH06507382A (ja) | 鎌状赤血球症の治療における分子矯正法 | |
| KR20070084123A (ko) | 양극성 장애 및 관련 증상의 치료 | |
| Absher et al. | Cognitive and noncognitive aspects of dementia syndromes: an overview | |
| Homeida et al. | Dapsone-induced optic atrophy and motor neuropathy | |
| ANTON et al. | Case report of carbamazepine treatment of organic brain syndrome with psychotic features | |
| DE69200365T2 (de) | Pharmazeutische Zusammensetzung zur Verbesserung von Dysuria. | |
| Chia et al. | Parkinson's disease in Taiwan: an analysis of 215 patients | |
| CA2049977A1 (en) | Nootropic agent | |
| JP5459934B2 (ja) | 神経接続欠陥、例えば精神分裂病及び自閉症の治療においてエポチロン（ｅｐｏｔｈｉｌｏｎｅ）を使用する方法 | |
| JPH05163144A (ja) | アルツハイマー型痴呆改善剤 | |
| JP4120713B2 (ja) | 多発性硬化症治療剤 | |
| US20250041248A1 (en) | Alz-801 for use in treating alzheimer's disease | |
| Engel et al. | Pernicious Anemia and Polycythemia Vera in One Patient: Report of Case and Review of the Literature | |
| HK1002153B (en) | Use of n-(2,6-dimethylphenyl)-2-(2-oxo-1-pyrrolidinyl) acetamide for the treatment of dementia | |
| Wszolek et al. | Seizures after liver transplantation | |
| Fisher et al. | Seizure disorders | |
| Kakode et al. | Diverse presentations of phenytoin toxicity-presenile cataract, encephalopathy and peripheral neuropathy: a case series | |
| KR20250008441A (ko) | 질환의 치료 방법 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FF | Patent granted | ||
| KB | Patent renewed | ||
| KB | Patent renewed | ||
| KB | Patent renewed |